James Schmitz, DO
Family Practice · Charleston, ARNPI 1881681864
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 28.9% of the total. Among family practice clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$607
- Exact Sciences$209
- AbbVie$142
- Lilly USA, LLC$123
- Otsuka America Pharmaceutical, Inc.$111
- AstraZeneca$106
- plus $800 from 16 others
What the payments were for
- Food & beverage$2,06999%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 35 | $607 |
| Exact Sciences | 12 | $209 |
| AbbVie(2 entities) | 8 | $142 |
| Lilly USA, LLC | 8 | $123 |
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| AstraZeneca | 7 | $106 |
| Xeris Pharmaceuticals, Inc. | 6 | $104 |
| Pfizer | 6 | $101 |
| Johnson & Johnson | 6 | $98 |
| Novartis | 5 | $81 |
| Merck | 4 | $69 |
| Novo Nordisk | 4 | $65 |
| Antares Pharma, Inc. | 3 | $62 |
| Abbott | 3 | $50 |
| Amgen | 3 | $43 |
| Boehringer Ingelheim | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Strongbridge US Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,099 in reported general payments places this provider in the 95th percentile of 108 family practice providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $142,028 |
| EliquisApixaban | 370 | $140,108 |
| MounjaroTirzepatide | 104 | $116,016 |
| XareltoRivaroxaban | 116 | $64,492 |
| TrulicityDulaglutide | 24 | $38,424 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $26,416 |
| JardianceEmpagliflozin | 36 | $25,575 |
| LinzessLinaclotide | 37 | $24,722 |
| VraylarCariprazine Hcl | 12 | $19,873 |
| FarxigaDapagliflozin Propanediol | 21 | $18,483 |
| MyrbetriqMirabegron | 16 | $10,784 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $9,574 |
| CorlanorIvabradine Hcl | 11 | $9,509 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $9,420 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $123 | $154,439128 claims |
| Novo NordiskOzempic, Levemir | $65 | $145,070145 claims |
| PfizerEliquis | $101 | $140,108370 claims |
| Johnson & JohnsonXarelto | $98 | $64,492116 claims |
| AbbVieLinzess, Vraylar, Restasis | $142 | $51,11260 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $106 | $35,05787 claims |
| Boehringer IngelheimJardiance, Synjardy | $35 | $31,52047 claims |
| AmgenCorlanor | $43 | $9,50911 claims |
| MerckJanuvia | $69 | $6,85424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 family practice providers in Arkansas.
Other family practice in Charleston
- Karla Jones-MontgomeryLittle Rock$115
- Damian AllenJonesboro$73
- Emmanuel MacdonaldJonesboro$62
- Jeremy SaulRussellville$0
- Mark RuckerSpringdale$0
- Hunter JudkinsFayetteville$0
- Samuel StringfellowJonesboro$0
- Kelly DavisLittle Rock$0
- Stephanie HoFayetteville$0
- Agnes KwoFort Smith$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.